Literature DB >> 15534102

Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis.

Mark L Gonzalgo1, Srinivasan Yegnasubramanian, Gai Yan, Craig G Rogers, Theresa L Nicol, William G Nelson, Christian P Pavlovich.   

Abstract

PURPOSE: Preoperative histologic classification of solid renal masses remains limited with current technology. We determine the utility of molecular profiling based on quantitative methylation analysis for characterization of sporadic renal cell carcinoma. EXPERIMENTAL
DESIGN: Primary renal cell carcinomas representing three different histologic subtypes were obtained from a total of 38 patients who underwent radical nephrectomy for suspected malignant disease. Genomic DNA was isolated from tumors and was subjected to sodium bisulfite modification. The normalized index of methylation (NIM) for each sample was determined by quantitative real-time methylation-specific PCR at 17 different gene promoters. Hierarchical cluster analysis was performed by using an unsupervised neural network with binary tree topology.
RESULTS: The majority of gene promoters that were analyzed in this study demonstrated very low levels of methylation (NIM <1.0). The RASSF1A gene promoter, however, was methylated in 30 of 38 (79%) cases. The frequency of RASSF1A methylation in papillary, clear-cell, and oncocytoma subtypes was 100, 90, and 25%, respectively. The highest levels of RASSF1A methylation were observed in the papillary (mean NIM = 78.9) and clear-cell (mean NIM = 13.4) subtypes. The vast majority of oncocytomas were completely unmethylated, and none demonstrated >1% methylation (mean NIM = 0.11). Hierarchical cluster analysis based on quantitative methylation levels resulted in stratification of sporadic renal cell carcinomas into their discrete histologic subtypes.
CONCLUSIONS: Classification of sporadic renal cell carcinomas into histologic subtypes can be accomplished via multigene quantitative methylation profiling. Validation of this approach and selection of appropriate methylation markers may ultimately lead to use of this technology in the preoperative assessment of suspicious renal masses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15534102     DOI: 10.1158/1078-0432.CCR-03-0692

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

Review 1.  Epigenetics of kidney cancer and bladder cancer.

Authors:  Amanda M Hoffman; Paul Cairns
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

2.  Basal-like breast cancer displays distinct patterns of promoter methylation.

Authors:  Ji Shin Lee; Mary Jo Fackler; Jae Hyuk Lee; Chan Choi; Min Ho Park; Jung Han Yoon; Zhe Zhang; Saraswati Sukumar
Journal:  Cancer Biol Ther       Date:  2010-06-18       Impact factor: 4.742

Review 3.  Epigenetic diagnostics of cancer--the application of DNA methylation markers.

Authors:  Jaroslaw Paluszczak; Wanda Baer-Dubowska
Journal:  J Appl Genet       Date:  2006       Impact factor: 3.240

Review 4.  Adjuvant therapy for high-risk renal cell carcinoma patients.

Authors:  David A Kunkle; Naomi B Haas; Robert G Uzzo
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

5.  Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.

Authors:  Frederic J Reu; Douglas W Leaman; Ratan R Maitra; Soo In Bae; Leonid Cherkassky; Mark W Fox; Donald R Rempinski; Normand Beaulieu; A Robert MacLeod; Ernest C Borden
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

Review 6.  The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments.

Authors:  Javier C Angulo; Claudia Manini; Jose I López; Angel Pueyo; Begoña Colás; Santiago Ropero
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

7.  Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma.

Authors:  M R Morris; C Ricketts; D Gentle; M Abdulrahman; N Clarke; M Brown; T Kishida; M Yao; F Latif; E R Maher
Journal:  Oncogene       Date:  2010-02-15       Impact factor: 9.867

8.  Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics.

Authors:  Mark R Morris; Eamonn R Maher
Journal:  Genome Med       Date:  2010-09-03       Impact factor: 11.117

9.  Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors.

Authors:  Giorgio Malpeli; Eliana Amato; Mario Dandrea; Caterina Fumagalli; Valentina Debattisti; Letizia Boninsegna; Giuseppe Pelosi; Massimo Falconi; Aldo Scarpa
Journal:  BMC Cancer       Date:  2011-08-12       Impact factor: 4.430

10.  The epigenetics of renal cell tumors: from biology to biomarkers.

Authors:  Rui Henrique; Ana Sílvia Luís; Carmen Jerónimo
Journal:  Front Genet       Date:  2012-05-30       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.